Despite tremendous research efforts in universities and pharmaceutical companies, effective drugs are still laking for the treatment of Alzheimer's disease (AD). The biochemical mechanisms of this devastating neurodegenerative disease have not yet been clearly understood. Beside a small percentage of cases with early-onset disease having a genetic origin (< 5%, familial AD), most patients develop in elderly a sporadic form due to the multiple and complex parameters of aging. Consequently, AD is spreading in all countries with a long life-expectancy. AD is characterized by deposition of senile plaques made of β-amyloid proteins (Aβ) and by hyperphosphorylation of tau proteins, which have been considered as the main drug targets up to now. However, antibodies targeting amyloid aggregates, as well as enzyme inhibitors aiming to modify the amyloid precursor protein processing, have failed to improve cognition in clinical trials. Then, to set up effective drugs, it is urgent to enlarge the panel of drug targets. Evidences of the link between AD and redox metal dysregulation have also been supported by post-mortem analyses of amyloid plaques, which contained accumulation of copper, iron, and zinc by 5.7, 2.8, and 3.1 times the levels observed in normal brains, ? Alzheimer's disease: deregulation of redox metals Cu, Fe in the brain Cu-Aβ Cu-proteins